Summary WHO SAGE conclusions and recommendations on Vaccine Hesitancy

Vaccine hesitancy is a complex and rapidly changing global problem that requires ongoing monitoring. WHO definition of vaccine hesitancy:

Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services. Vaccine hesitancy is complex and context specific varying across time, place and vaccines. It includes factors such as complacency, convenience and confidence.

Understanding hesitancy

Addressing vaccine hesitancy within a country and/or subgroup requires an understanding of the magnitude and setting of the problem, diagnosis of the root causes, tailored evidence-based strategies to address the causes, monitoring and evaluation to determine the impact of the intervention and whether vaccine acceptance has improved, and ongoing monitoring for possible recurrence of the problem.

When addressing vaccine hesitancy, it must be noted that there are many determinants of vaccine hesitancy. WHO grouped these determinants into contextual, individual and group influences and vaccine/vaccination specific issues. (See Table 1) Countries need to adequately assess which underlying determinant(s) is the factor driving vaccine hesitancy in their setting.

Resources for assessing and addressing hesitancy

A compendium of survey questions to assess the underlying determinant of vaccine hesitancy was developed by the SAGE Working Group, though the need remains for countries to validate these questions in low, middle and high income settings¹. If doing so, findings should be shared to help inform future development of such tools.



One of other potentially promising tools is the WHO EUR Guide to Tailoring Immunization Program (TIP). The TIP framework helps to a) Identify and prioritize vaccine hesitant populations and subgroups, b) Diagnose the demand and supply—side barriers to vaccination in these populations, c) Design evidence—informed responses to vaccine hesitancy appropriate to the setting, context and hesitant population². This framework is currently being adapted for global use.

There is no single intervention strategy that addresses all instances of vaccine hesitancy. Based on the Systematic Review of Strategies to Address

Vaccine Hesitancy, the most effective interventions addressing the outcome of vaccination uptake are multi-component interventions versus single-component. These interventions should be dialogue-based and directly targeted at the unvaccinated or under-vaccinated populations and the specific populations (e.g., local community, HCW).

 $^{^{1} \ \}text{http://www.who.int/immunization/sage/meetings/2014/october/2_SAGE_Appendicies_Background_final.pdf?ua=1}$

² http://www.euro.who.int/ data/assets/pdf file/0003/187347/The-Guide-to-Tailoring-Immunization-Programmes-TIP.pdf

The interventions should address the specific determinants underlying vaccine hesitancy. Strategies may include:

- Engagement of religious or other influential leaders to promote vaccination in the community
- Social mobilisation
- · Mass media
- Improving convenience and access to vaccination
- Mandating vaccinations / sanctions for non-vaccination
- Employing reminder and follow-up
- Communications training for HCW
- Non-financial incentives
- Aim to increase knowledge, awareness about vaccination

Considerations for countries

Immunization programs need to incorporate the ones that fit their setting and resources into their program in order to support vaccine uptake.

Countries need to take into consideration that in low vaccine uptake situations, where lack of available services is the major factor impairing adequate vaccination coverage, vaccine hesitancy can be present but is not the priority to address and should not be the focus of their resources.

Countries should incorporate a plan to measure and address vaccine hesitancy into their country's immunization program as part of good program practices, using and validating the compendium of potential vaccine hesitancy survey questions as one of other possible tools as this facilitates intercountry comparisons. Countries should further undertake education and training of health care workers to empower these to address vaccine hesitancy issues in patients and parents. In addition, vaccine hesitant behaviours within health care workers should be addressed.

Relevant training, of nursing, medical and other health care professional students, needs to be included into academic curricula. Educating younger individuals about vaccines could shape future vaccine beliefs and behaviour. As part of good immunization program practice, civil society organizations, local communities and health care workers need to be involved in supporting vaccination programs, in enhancing demand for vaccination and in helping to address vaccine hesitancy depending upon the underlying factors. Country information on vaccine hesitancy and lessons learned should be shared among member states. In addition National Immunization Technical Advisory Groups (NITAGs) may be a valuable resource to address vaccine hesitancy and should give consideration to issues of vaccine hesitancy in their country.

Based on the recommendations of the SAGE Working Group, efforts are now underway to define and develop any additional tools to help understand and develop interventions on hesitancy.

For more information, see the report of the WHO SAGE Vaccine Hesitancy Working Group.³

http://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf?ua=1

Table.1 A model to identify determinants of vaccine hesitancy

| CONTEXTUAL | a.Communication | b. Influential | c.Historical | d.Religion/culture/ge | e. Politics/policies | f.Geographic | g.Pharmaceutic |
|-------------------|-----------------------------------|-----------------------------|-------------------------------|-------------------------------|----------------------|-----------------------|------------------------------------|
| <u>INFLUENCES</u> | and media | leaders, | influences | nder/socio-economic | (Mandates) | barriers | al industry |
| | environment | gatekeepers and | | | | | |
| Influences | | anti- or pro- | Historic influences | A few examples of the | Vaccine mandates | A population can | Industry may be |
| arising due | Media and social | vaccination | such as the | interplay of | can provoke vaccine | have general | distrusted and |
| to historic, | media can create | lobbies | negative experience | religious/cultural | hesitancy not | confidence in a | influence |
| socio- | a negative or | | of the Trovan trial | influences include: | necessarily because | vaccine and health | vaccine |
| | positive vaccine | Community | in Nigeria can | | of safety or other | service, and be | hesitancy when |
| cultural, | sentiment and | leaders and | undermine public | Some religious | concerns, but due to | motivated to receive | perceived as |
| environment | can provide a | influencers, | trust and influence | leaders prohibit | resistance to the | a vaccine but | driven only by |
| al, health | platform for | including religious | vaccine acceptance, | vaccines | notion of forced | hesitate as the | financial |
| system/instit | lobbies and key | leaders in some | as it did for polio, | Company to the second | vaccination | health center is too | motives and not |
| utional, | opinion leaders to | settings, celebrities in | especially when combined with | Some cultures do not | | far away or access is | in public health interest; This |
| economic or | influence others; social media | others, can all | pressures of | want men vaccinating children | | difficult. | can extend to |
| political | allows users to | have a significant | influential leaders | Ciliuren | | | distrust in |
| factors | freely voice | influence on | and media. A | Some cultures value | | | government |
| | opinions and | vaccine | community's | boys over girls and | | | when perceived |
| | experiences and it | acceptance or | experience isn't | fathers don't allow | | | that they are |
| | can facilitate the | hesitancy. | necessarily limited | children to be | | | also being |
| | organization of | , | to vaccination but | vaccinated), | | | pushed by |
| | social networks | | may affect it. | ,, | | | industry and not |
| | for or against | | | | | | transparent. |
| | vaccines . | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| m vs. |
|-----------|
| |
| |
| rmful |
| |
| eptance |
| ı is |
| by peer |
| social |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| c) ! Ł |

| VACCINE/ | a. Risk/ Benefit | b. Introduction of | c. Mode of | d. Design of | e. Reliability | f. Vaccination | g. Costs | h. Role of |
|---------------|-------------------|--------------------|----------------|----------------|----------------------|-----------------------|-------------------|-----------------------|
| VACCINATION | (scientific | a new vaccine or | administrati | vaccination | and/or source of | schedule | | healthcare |
| -specific | evidence) | new formulation | on | program/Mo | vaccine supply | | An individual | professionals |
| _ | | | | de of | | Although there may | may have | |
| <u>issues</u> | Scientific | Individuals may | Mode of | delivery | Individuals may | be an appreciation | confidence in a | |
| | evidence of | hesitate to accept | administratio | | hesitate if they do | for the importance | vaccine's safety | Health care |
| Directly | risk/benefit and | a new vaccine | n can | | not have | of preventing | and the system | professionals |
| related to | history of safety | when they feel it | influence | Delivery | confidence in the | individual vaccine | that delivers it, | (HCP)are important |
| vaccine or | issues can | has not been | vaccine | mode can | system's ability to | preventable | be motivated to | role models for their |
| vaccination | prompt | used/tested for | hesitancy for | affect vaccine | provide vaccine(s) | diseases, there may | vaccinate, but | patients; if HCPs |
| racomation | individuals to | long enough or | different | hesitancy in | or might not have | be reluctance to | not be able to | hesitate for any |
| | hesitate, even | feel that the new | reasons. E.g. | multiple | confidence in the | comply with the | afford the | reason (e.g. due to |
| | when safety | vaccine is not | oral or nasal | ways. Some | source of the | recommended | vaccine or the | lack of confidence in |
| | issues have | needed, or do not | administratio | parents may | supply (e.g. if | schedule (e.g. | costs associated | a vaccine's safety or |
| | been clarified | see the direct | ns are more | not have | produced in a | multiple vaccines or | with getting | need) it can |
| | and/or | impact of the | convenient | confidence in | country/culture the | age of vaccination). | themselves and | influence their |
| | addressed | vaccine (e.g. HPV | and may be | a vaccinator | individual is | | their child(ren) | clients' willingness |
| | e.g. suspension | vaccine preventing | accepted by | coming | suspicious of); | Vaccination | to the | to vaccinate |
| | of rotavirus | cervical cancer). | those who | house-to- | health workers may | schedules have | immunization | |
| | vaccine due to | Individuals may be | find | house; or a | also be hesitant to | some flexibility that | point. | |
| | intussusception; | more willing (i.e. | injections | campaign | administer a | may allow for slight | Alternatively, | |
| | Guillain-Barre | not complacent) | fearful or | approach | vaccine (especially | adjustment to meet | the value of the | |
| | syndrome | to accept a new | they do not | driven by the | a new one) if they | individual needs | vaccine might | |
| | following swine | vaccine if | have | government. | do not have | and preferences. | be diminished if | |
| | flu vaccine | perception of the | confidence in | Alternatively | confidence that the | While this may | provided for | |
| | (1976) or | VPD risk is high. | the health | if a health | supply will continue | alleviate hesitancy | free. | |
| | narcolepsy | | workers skills | centre is too | as it affects their | issues, | | |
| | (2011) following | | or devices | far or the | clients trust in | accommodating | | |
| | (A)H1N1 | | used. | hours are | them. | individual demands | | |
| | vaccination; | | | inconvenient | Caregivers may not | are not feasible at | | |
| | milder, local | | | | have confidence | a population level. | | |
| | adverse events | | | | that a needed | | | |
| | can also | | | | vaccine and or | | | |
| | provoke | | | | health staff will be | | | |
| | hesitancy. | | | | at the health | | | |
| | | | | | facility if they go | | | |
| | | | | | there. | | | |